This document summarizes a research study that aimed to improve prediction of in vitro fertilization (IVF) outcomes for women with low levels of anti-Müllerian hormone (AMH) prior to their first IVF cycle. The study found that levels of dehydroepiandrosterone sulfate (DHEAS), a hormone that declines with age, provided additional predictive power beyond age alone. A model combining age cutoff of 37.5 years and DHEAS cutoff of 5.7 μmol/L improved the ability to predict clinical pregnancy compared to age alone. The results suggest DHEAS levels may be associated with oocyte quality and that assessing both DHEAS and age could enhance counseling of women expected to be
Infertilità inspiegata o Sine causa
Quali sono i 3 esami indispensabili nella diagnostica di infertilità
Diagnosi di ovulazione
Esame del liquido seminale
Isterosalpingografia
How to prevent occurrence of severe ovarian hyperstimulation in IVF. Is there a way ? this talk will present a pilot randomised study that may shed the light on this
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...lukeman Joseph Ade shittu
The case presented describes a live birth following treatment of a 35-year-old woman with fallopian tube sperm perfusion (FTSP) using donor sperm after three-repeated unsuccessful courses of In-vitro fertilization (IVF) with Percutaneous Epididymal Sperm Aspiration (PESA), Testicular Sperm Extraction (TESE), and donor sperm. The indication of FTSP is hereby explored and discussed.
Update on LETROZOLE Current Guidelines for Ovulation Induction Dr. Sharda Jain Lifecare Centre
Update on LETROZOLE Current Guidelines for Ovulation Induction
LET NOT FORGET
WHY
??
LETROZOLE was withdrawn from
Indian market (2012)
“SAFETY ISSUES”
“Could Be Teratogenic In Human”?
How to choose between drugs: efficacy / safety and cost effectiveness. In IVF, we have GnRHagonist and antagonists: how to choose based on best available evidence. This talk may help to answer this question
Ovarian Hyperstimulation in Intrauterine InseminationElmar Breitbach
Intrauterine insemination is well established in the treatment of infertility. But which pretreatment leads to the best results? Do we have to trigger ovulation? What about luteal phase support? Whar patients do have the best chances? When do we have to switch to IVF?
Evidence based answers to these questions an a bit of experience based suggestions.
Recent evidence based guideline regarding Ovarian drilling very helpful for Gynaecologist, laparoscopic surgeon, Infertility specialist, Post doctoral fellows and post graduates
Infertilità inspiegata o Sine causa
Quali sono i 3 esami indispensabili nella diagnostica di infertilità
Diagnosi di ovulazione
Esame del liquido seminale
Isterosalpingografia
How to prevent occurrence of severe ovarian hyperstimulation in IVF. Is there a way ? this talk will present a pilot randomised study that may shed the light on this
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...lukeman Joseph Ade shittu
The case presented describes a live birth following treatment of a 35-year-old woman with fallopian tube sperm perfusion (FTSP) using donor sperm after three-repeated unsuccessful courses of In-vitro fertilization (IVF) with Percutaneous Epididymal Sperm Aspiration (PESA), Testicular Sperm Extraction (TESE), and donor sperm. The indication of FTSP is hereby explored and discussed.
Update on LETROZOLE Current Guidelines for Ovulation Induction Dr. Sharda Jain Lifecare Centre
Update on LETROZOLE Current Guidelines for Ovulation Induction
LET NOT FORGET
WHY
??
LETROZOLE was withdrawn from
Indian market (2012)
“SAFETY ISSUES”
“Could Be Teratogenic In Human”?
How to choose between drugs: efficacy / safety and cost effectiveness. In IVF, we have GnRHagonist and antagonists: how to choose based on best available evidence. This talk may help to answer this question
Ovarian Hyperstimulation in Intrauterine InseminationElmar Breitbach
Intrauterine insemination is well established in the treatment of infertility. But which pretreatment leads to the best results? Do we have to trigger ovulation? What about luteal phase support? Whar patients do have the best chances? When do we have to switch to IVF?
Evidence based answers to these questions an a bit of experience based suggestions.
Recent evidence based guideline regarding Ovarian drilling very helpful for Gynaecologist, laparoscopic surgeon, Infertility specialist, Post doctoral fellows and post graduates
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its ApplicationsDr. Rajesh Bendre
Serum anti-Mullerian hormone (AMH) is a unique biomarker that has a critical role in folliculogenesis as well as steroidogenesis within ovaries. Secretion from preantral and early antral follicles renders AMH as the earliest marker to show ovarian reserve decline.
Current markers for ovarian reserve are AMH & Antral follicle counts. AMH levels have been used to stratify patients with respect to fertility & further used in appropriate treatment options for successful pregnancy in an infertile couple.
Intrauterine insemination (IUI) is procedure which involves placing sperm inside a woman's uterus to facilitate fertilization. The ovaries are stimulated with tablets and injections and then monitored for the probable time of ovulation. For more info visit :-//www.newhopeivf.com/intrauterine-insemination-iui.html
Anti-Müllerian Hormone (AMH) is critical for physiologic involution of the Mullerian ducts during sexual differentiation in the male foetus.
In women,AMH is a product of the small antral follicles in the ovaries and serves to function as an autocrine and paracrine regulator of follicular maturation
Are we giving much importance to AMH in infertility practice?Sujoy Dasgupta
Dr Sujoy Dasgupta delivered "Kamini Rao Oration" on "Are we giving much importance to AMH in infertility practice?" in East Zone Yuva FOGSI Conference organized by Imphal Obstetric and Gynaecological Society (IOGS) on 24 December, 2023
OVERVIEW
Aim
Definition
Prerequisites
Individualisation of patient.
Ohss free IUI. Clinic
{Strict cancellation of cycle if OHSS is suspected}
Newer trends
Sucess Rates in IUI with COH
PROGNOTIC FACTORS to increase Pregnancy Rates..& discussion
Oration delivered by Dr Sujoy Dasgupta at Yuvacon, conference organized by the BOGS (Bengal Obstetric and Gynaecological Society) held on 22-23 April, 2023
MONITORING PITUITARY DOWN-REGULATION
If GnRH Agonist is started in the late luteal phase a menstrual bleeding normally indicates that the estrogen is low and FSH can be started.
Blood tests will clearly confirm down-regulation – ovarian/pituitary hormones.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Short predikcija ishoda ivf postupaka u zena s niskim serumskim vrijednostima amh skracena
1. Predikcija ishoda IVF postupaka u
žena s niskim serumskim
vrijednostima AMH
Miro Šimun Alebić
Odjel za humanu reprodukciju
Klinika za ženske bolesti i porode
KB Merkur
2. AMH
• Anti-Müllerian hormone (AMH)
– dimeric glycoprotein, a member of the
transforming growth factor-beta superfamily
(Jost, 1946; Cate et al., 1986)
– In women,
• produced by granulosa cells of pre-antral and small
antral follicles (Weenen et al., 2004)
• main physiological role - inhibition of the early stages
of follicular development (Themmen, 2005; Visser and
Themmen, 2005).
3. AMH
• AMH – prediction of ovarian response
– in prediction of the number of oocytes retrieved
basal AMH serum levels are, at least, as good as
antral follicle count (AFC) (Broer et al., 2008, La
Marca et al., 2010)
4. Pregnancy chances
– oocyte yield: positively affects the pregnancy
chances (Ulug et al., 2003; Baka et al., 2006;
Timeva et al., 2006)
– poor responders have a lower pregnancy rate
compared with normal responders (Biljan et al.,
2000; de Sutter and Dhont, 2003; Galey-Fontaine
et al., 2005; Baka et al., 2006; Timeva et al.,2006;
van der Gaast et al., 2006; Saldeen et al., 2007;
Hendriks et al., 2008; Zhen et al., 2008)
5. POOR
• poor ovarian response (POOR) is associated
– mainly,
• reduced number of FSH-sensitive follicles, most
frequently linked to the condition known as diminished
ovarian reserve.
– rarely,
• suboptimal exposure to gonadotrophins (Maheshwari
et al.,2007)
• FSH hyposensitivity (FSH receptor subtypes less
sensitive to exogenous gonadotrophins (Simoni et al.,
2002).
6. Pregnancy chances in POORs
• POOR definition requires, at least, 1 IVF cycle
(Ferrareti et al., 2011)
• identification of those among poor
responders who still have an acceptable
prognosis
• counseling on whether it is worthwhile to
start or continue with IVF (Oudendijk et al.,
2012)
7. Pregnancy chances in POORs
• BMI: >30 kg/m2 negatively influence the
pregnancy chances (Orvieto et al., 2009)
• FSH: >12 IU/L significantly lowers the
pregnancy rates (Galey-Fontaine et al., 2005)
8. Expected POOR
• expected POOR could be diagnosed BEFORE
first IVF cycle according to AMH, AFC…
• AMH – prediction of POOR
– in response to FSH, reported sensitivity and
specificity ranged between 44–97% and 41–100%,
respectively (La Marca et al., 2010)
9. Pregnancy chances
– AMH is not suitable to be used as a single
predictor of pregnancy chances following IVF
(Broer et al., 2009; Weghofer et al.,2011;
Ferraretti et al., 2011)
– age: negatively associated with pregnancy
chances (Hanoch et al., 1998; de Sutter and Dhont,
2003; Ulug et al.,2003; aley-Fontaine et al., 2005;
Zhen et al., 2008)
10. Pregnancy chances before first IVF
cycle
•multivariate age-AMH model significantly improved LB
prediction accuracy of both univariate and age models
• ROC-AUCAMH-age 0.66 (95% CI 0.61–0.72) vs
• ROC-AUCAMH 0.57, (95% CI 0.52–0.61,P<0.05) and
• ROC-AUCage(95% CI 0.52–0.59,P<0.05)
•in the same age category, AMH is able to distinguish
between pregnancy and non-pregnancy (La Marca et
al., 2011)
11. Research
• in the same AMH and age category, there are
still patients who achieve pregnancy and
those who do not
• is it possible to identify those with acceptable
pregnancy prospects among expected POORs
prior to the first IVF cycle?
12. Research
• Objective:
– to investigate
• whether any of the endocrine and/or clinical
characteristic (s) obtainable prior to the first (GnRH
antagonist )IVF cycle could improve the accuracy of IVF
outcome prediction based on the female age alone in
expected poor responders (by low AMH levels)
– to identify parameter(s) able to discriminate
patients with favorable and unfavorable prognosis
within the same age and AMH category
13. Uvod
• groundwork (N=1088):
1. the optimal cut-off for the number of oocytes
retrieved (NOR) to discriminate between
pregnancy and non- pregnancy
- AUC 0,61; 95% CI 0,58-0,64; P<0,001
<3 oocytes:
+LR for non-pregnancy of 2.82; 95%CI 2.0 4.0
14. Research
• groundwork
2. to set the AMH cutoff for POOR (<3
oocytes):
AUC= 0,71; 95% CI 0,680,74; P<0,001;
<6.5 pmol/L
+LR 3.18; 95%CI 2.6 - 3.9
15. Istraživanje
• M&M:
Inclusion criteria:
1. serum AMH concentration <6.5 pmol/L
2. null gravidity
3. normal uterus and uterine cavity
4. no history of pelvic disease or surgery
5. no history of the use of medications that could interfere with basal hormone
status,
6. sperm count of, at least, 1 × 106 /mL
7. first IVF/ICSI cycle,
8. AMH and other laboratory tests values obtained within three months
preceding controlled ovarian stimulation,
9. a fixed dose of 300 I.U. hMG from the day 3; GnRH antagonist protocol
• N=129
16. Research
• main outcome:
– AUC-ROC of model combining age and other
potential predictive factors for the clinical
pregnancy.
• study design:
– retrospective study
18. Research
• LRA:
– univariate showed significant predictive power for both,
age and DHEAS
– multivariate excluded age from the predictive model
leaving only DHEAS as predictive for pregnancy (DHEAS
1,59; 95%CI 1.58-2.2)
• the negative correlation between age and DHEAS could
not entirely explain the association between DHEAS
and pregnancy prospects
• the usefullness of continous multivarate model was
failed to be demonstrated
19. Research
• however, discriminative capacity of DHEAS was not
demonstrated to be higher than age
– AUC-ROCDHEAS
0.726 (95%CI 0.641–0.801)
– AUC-ROCage
0.662 (95%CI 0.573–0.743)
= 0.522
• since age is an easy-to-obtain parameter, the use of
DHEAS, as a single predictor, instead of age could not
be advised
20. Research
• therefore, according to cut-offs derived by ROC
curve analysis:
– age - 37.5 y (OR=6.7; 95% CI 1.5–31.2)
– DHEAS - 5.7 mol/L (OR 7.9; 95% CI 2.5–25.4)
21. Research
• the usefullness of combined age and DHEAS
categoric model for pregnancy prediction was
assesed by comparison with discriminative capacity
of univariate age model
AUC-ROCage-DHEAS 0.796 (95%CI 0.716–0.862)
AUC-ROCage
0.662 (95%CI 0.573–0.743)
= 0.013
• combining information on DHEAS and age could
improve the ability to predict pregnancy compared
to the information of age alone
24. Research
• Discussion:
• DHEAS is a sulfated metabolite of DHEA and
acts as a intraovarian hormone precursor for
active androgens and estrogens (Casson et
al., 2000)
• DHEAS to DHEA conversion take place in GCsulphatase (Bonser et al., 2000)
25. Research
• Discussion:
• decline linearly with age (Labrie et al., 1997)
• may have beneficial effect on age-related
conditions (van Muhlen et al., 2007)
• the beneficial effect of DHEA
supplementation in some patients with
diminished ovarian reserve (Gleicher and
Barad, 2011).
26. Research
• Discussion:
• potentialy, sufficient quantities of DHEAS and
its metabolites in the oocyte
microenviroment are needed to ensure
adequate steroidogenesis and sufficient
oocyte quality
27. Research
• Discussion:
• hipotheticaly, DHEAS deficiency in younger
patients reduce their pregnancy chances to
the level inherent to the higher age
categories
28. Research
• Discussion:
• not all poor responders are similar in terms
of loss of oocyte quality
• the link between remaining quantity of antral
follicles and the quality of the oocytes held
within these follicles is missing (Oudendijk et
al., 2012)
30. Research
• Conclusion:
• adding information on DHEAS to female age could
improve the prediction of clinical pregnancy prior to
the first IVF cycles
• improved counseling accuracy regarding the
probabilities for successful IVF treatment in women
with low AMH who were younger than 37.5 years
• hypotheticaly, observed association between DHEAS
and pregnancy chances could be explained by the
association of DHEAS and oocyte quality